Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Senate Health Care panel hears call to expand reporting on manufacturer-funded patient assistance programs
Summary
State staff told the Senate Committee on Health Care that Oregon's drug-price reporting misses most manufacturer-funded patient assistance programs and recommended a new annual report requiring manufacturers to submit PAP data for all drugs that benefit Oregon consumers.
The Senate Committee on Health Care on Feb. 2 heard state agency staff recommend expanding Oregon's prescription drug transparency reporting to require annual disclosure of manufacturer-funded patient assistance program (PAP) data for all programs that provide benefits to Oregon consumers.
The recommendation, presented by Jesse O'Brien, policy manager at the Division of Financial Regulation (Department of Consumer and Business Services), and Sarah Young, executive director of the Oregon Prescription Drug Affordability Board, would change the program's reporting trigger so PAP data are collected for all programs rather than only as part of annual reports triggered by large price increases.
Why it matters: Presenters told the committee that current law requires manufacturers to report PAP information only when a drug…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
